Ginkgo Bioworks Holdings, Inc. (DNA)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cell Engineering Revenue	132.75M	173.97M
Cell Engineering Revenue Growth	-23.70%	21.21%
Biosecurity Service Revenue	37.41M	53.07M
Biosecurity Service Revenue Growth	-29.51%	-32.80%
Total Biosecurity Revenue	37.41M	53.07M
Total Biosecurity Revenue Growth	-29.51%	-50.83%
Revenue (Total)	170.16M	227.04M
Revenue (Total) Growth	-25.06%	-9.71%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cell Engineering Operating Income	-95.53M	-218.57M
Biosecurity Operating Income	-18.93M	-30.62M
Corporate Operating Income	-200.82M	-310.57M
Operating Income (Other)	-	-
Operating Income (Total)	-315.28M	-559.76M

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
New Programs	52.00
New Programs Growth	-33.33%
Current Active Programs	176.00
Current Active Programs Growth	8.64%
Cumulative Programs	294.00
Cumulative Programs Growth	21.49%

Updated Dec 31, 2025. Data Source: Fiscal.ai.